Surmodics, Inc. (NASDAQ:SRDX) Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its position in Surmodics, Inc. (NASDAQ:SRDXFree Report) by 1.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,699 shares of the company’s stock after purchasing an additional 638 shares during the period. Principal Financial Group Inc. owned approximately 0.26% of Surmodics worth $1,120,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in SRDX. Legal & General Group Plc lifted its position in shares of Surmodics by 34.2% in the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after buying an additional 880 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Surmodics during the fourth quarter valued at about $217,000. Polymer Capital Management US LLC bought a new stake in shares of Surmodics in the 4th quarter valued at approximately $255,000. DeepCurrents Investment Group LLC bought a new stake in shares of Surmodics in the 4th quarter valued at approximately $260,000. Finally, Lighthouse Investment Partners LLC acquired a new position in shares of Surmodics in the 4th quarter worth approximately $262,000. 96.63% of the stock is currently owned by institutional investors and hedge funds.

Surmodics Stock Performance

Shares of NASDAQ:SRDX opened at $30.21 on Friday. The company’s 50 day simple moving average is $29.41 and its 200 day simple moving average is $31.13. The stock has a market capitalization of $432.00 million, a price-to-earnings ratio of -21.73 and a beta of 1.31. The company has a debt-to-equity ratio of 0.27, a current ratio of 5.14 and a quick ratio of 3.99. Surmodics, Inc. has a 1 year low of $26.00 and a 1 year high of $41.88.

Surmodics (NASDAQ:SRDXGet Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.07). Surmodics had a negative net margin of 16.34% and a negative return on equity of 7.10%. The company had revenue of $28.09 million during the quarter, compared to analyst estimates of $32.23 million. As a group, research analysts predict that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research report on Wednesday, April 30th.

Get Our Latest Stock Analysis on Surmodics

About Surmodics

(Free Report)

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

See Also

Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc. (NASDAQ:SRDXFree Report).

Institutional Ownership by Quarter for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.